Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
The liabilities associated with repurposing apramycin for the clinic: a genomic enzymology study of the unprecedented apramycin-resistance enzyme ApmA
FY 2018-19
Summary
The global threat of antibiotic resistance has created an urgent need for new antibiotics. With a considerable lack of new drugs in the pipeline, older classes of antibiotics are being reconsidered for their effectiveness in the clinic. The aminoglycoside apramycin has been traditionally used in veterinary medicine, however, it has now become an attractive candidate as a repurposed therapeutic. Due to its unique structure, apramycin has the potential to be the saving grace against priority pathogens when all other clinically relevant aminoglycosides, including the next-generation aminoglycoside plazomicin, are ineffective. Prior to its introduction into the clinic it is important to understand any resistance mechanisms that may become a liability or threaten apramycin's success as a drug. As such, the goal of this project is to understand the recently discovered resistance element apmA. This work aims to provide an understanding of the mechanism of resistance for the encoded enzyme and how it has evolved to modify apramycin along with other aminoglycosides. Originally found in bacterial isolates from farm animals, this gene will render apramycin ineffective in the clinic against pathogens deemed a priority by the World Health Organization. Results gathered thus far show the encoded protein to be a from a family of enzymes that have not yet been encountered in hospitals with respect to aminoglycoside resistance. Researchers will be able to use the knowledge obtained through this work to better guide the development of apramycin analogues that can circumvent this unforeseen form of resistance.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
404179
Name
Bordeleau Emily A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The liabilities associated with repurposing apramycin for the clinic: a genomic enzymology study of the unprecedented apramycin-resistance enzyme ApmA
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Antibiotic Resistance; Antibiotics; Crystallography; Enzymology; Evolution; Genomic Enzymology; Kinetics
Abstract
The global threat of antibiotic resistance has created an urgent need for new antibiotics. With a considerable lack of new drugs in the pipeline, older classes of antibiotics are being reconsidered for their effectiveness in the clinic. The aminoglycoside apramycin has been traditionally used in veterinary medicine, however, it has now become an attractive candidate as a repurposed therapeutic. Due to its unique structure, apramycin has the potential to be the saving grace against priority pathogens when all other clinically relevant aminoglycosides, including the next-generation aminoglycoside plazomicin, are ineffective. Prior to its introduction into the clinic it is important to understand any resistance mechanisms that may become a liability or threaten apramycin's success as a drug. As such, the goal of this project is to understand the recently discovered resistance element apmA. This work aims to provide an understanding of the mechanism of resistance for the encoded enzyme and how it has evolved to modify apramycin along with other aminoglycosides. Originally found in bacterial isolates from farm animals, this gene will render apramycin ineffective in the clinic against pathogens deemed a priority by the World Health Organization. Results gathered thus far show the encoded protein to be a from a family of enzymes that have not yet been encountered in hospitals with respect to aminoglycoside resistance. Researchers will be able to use the knowledge obtained through this work to better guide the development of apramycin analogues that can circumvent this unforeseen form of resistance.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bordeleau, Emily A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~